Press release
In-Depth Analysis of the Synagis Market: Growth Opportunities, Key Trends, and Forecast 2025-2034
Synagis
The increasing prevalence of chronic respiratory conditions is expected to drive the growth of the Synagis market in the future. Chronic respiratory conditions are long-term illnesses affecting the lungs and airways, resulting in persistent breathing difficulties. The rise in these conditions is attributed to factors like an aging population, smoking, lifestyle choices, genetic predispositions, and environmental pollution. Synagis (palivizumab) helps prevent severe respiratory syncytial virus (RSV) infections in high-risk infants and children, reducing complications in those with chronic respiratory conditions. For instance, in December 2023, Public Health Scotland reported that the prevalence of doctor-diagnosed asthma in 2022 was 16%, rising to 17% in 2022. Therefore, the increasing prevalence of chronic respiratory conditions is driving the growth of the Synagis market.
Get Your Synagis Market Report Here:
https://www.thebusinessresearchcompany.com/report/synagis-global-market-report
What Is the projected market size and growth rate for the synagis market?
The synagis market size has shown XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025, at a compound annual growth rate (CAGR) of XX%. The growth is attributed to rising spending on chronic illnesses, increased R&D investments, the growing disease burden, higher hospitalization rates, and the increasing prevalence of chronic respiratory conditions.
The Synagis market size is expected to see XX% FCAGR in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. Growth is driven by rising R&D expenditures, the increasing prevalence of RSV (Respiratory Syncytial Virus), growing demand for personalized medicine and telemedicine, the aging population, and the expanding pediatric population in emerging markets. Key trends include advancements in RSV treatment, biosimilar development, clinical trial outcomes, regulatory approvals, and the introduction of combination vaccines.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp
What new trends are reshaping the synagis market and its opportunities?
Acquiring drug permission from authorities is a key trend noticed in the synagis market as it obtains the prospect long-awaited preventive therapy for respiratory syncytial virus. Drug authorization is an evaluation and approval procedure undertaken by regulating authorities to ensure the safety, potency, and quality of a new drug for sale and use based on data from clinical trials. For instance, in September 2023, the India-based biopharmaceutical firm, AstraZeneca Pharma India Ltd., was granted the approval for palivizumab by the Central Drugs Standard Control Organisation (CDSCO). This prevents respiratory syncytial virus (RSV) and allows them to market the drug. This includes the palivizumab 100 mg/ml injection and is made available in 50 mg/0.5 ml and 100 mg/ml single-dose vials for intramuscular administration. The drug is recommended for infants born at up to 35 weeks of gestation, children who require treatment for bronchopulmonary dysplasia (BPD), and those suffering from hemodynamically significant congenital heart disease (CHD). This breakthrough approval sets a milestone in ameliorating RSV care in India as it becomes the first-ever preventive therapy against RSV available there.
What major market segments define the scope and growth of the synagis market?
The synagis market covered in this report is segmented -
1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis; Premature Infants With Bronchopulmonary Dysplasia (BPD); Congenital Heart Disease (CHD); Immunocompromised Infants And Children
2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL); 100 Milligrams (mg)/1 Milliliters (mL)
3) By Distribution Channel: Wholesale Distributors; Online Retailers
4) By End-User: Pediatric; Adults
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20304
Which region dominates the synagis market?
North America was the largest region in the synagis market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which key market leaders are driving the synagis industry growth?
Major companies operating in the synagis market are Swedish Orphan Biovitrum AB
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20304&type=smp
What Is Covered In The Synagis Global Market Report?
•Market Size Forecast: Examine the synagis market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the synagis market for a structured understanding.
•Key Players Overview: Analyze major players in the synagis market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the synagis market.
•Segment Contributions: Evaluate how different segments drive overall growth in the synagis market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the synagis market.
•Industry Challenges: Identify potential risks and obstacles affecting the synagis market.
•Competitive Landscape: Review strategic developments in the synagis market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release In-Depth Analysis of the Synagis Market: Growth Opportunities, Key Trends, and Forecast 2025-2034 here
News-ID: 3943771 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Synagis
Global Synagis Market Outlook 2025-2034: Trends, Innovations, And Future Outlook
"We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Projected Growth of the Synagis Market?
In recent times, the Synagis market has experienced an XX (HCAGR) increase. The market is expected to rise from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. This growth during the historical period…
Top Factor Driving Synagis Market Growth in 2025: Rising Prevalence Of Chronic R …
What Are the Projected Growth and Market Size Trends for the Synagis Market?
Recent years have seen an $XX (CAGR) increase in the size of the Synagis market. Projected growth is evident as its value is expected to rise from $XX million in 2024 to $XX million in 2025, with a Compound Annual Growth Rate (CAGR) of $XX%. This upward trend during the historical period is ascribed to factors such as…
Respiratory Syncytial Virus Infections- Market Insights, Epidemiology and Market …
Respiratory Syncytial Virus Infections
Wiseguyreports.Com Adds “Respiratory Syncytial Virus Infections Market -Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database.
Description:
The Respiratory Syncytial Virus Infections- Market Insights, Epidemiology and Market Forecast-2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and…
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis An …
Summary
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such…
Synagis (Pediatric RSV) - Forecast And Market Analysis To 2022
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Synagis (Pediatric RSV) Forecast and Market Analysis to 2022. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected persons sneeze or…
Respiratory Syncytial Virus (RSV) - Opportunity Analysis, Trend, Growth and Fore …
Researchmoz added Most up-to-date research on "OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024" to its huge collection of research reports.
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from…
